Hígado Graso (NASH)
[Figura representativa extraída de PubMed Central - PMC13476547]
Fuente oficial abierta: NCBI/PMC (PMC13476547)
# Metabolomic Profiling of Microfluidic Hepatic Models: Unraveling Fatty Acid Lipotoxicity and Sex-Dimorphic Pathways in MASLD/NASH
## Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction-associated steatohepatitis (NASH), are characterized by aberrant hepatic lipid accumulation and lipotoxic stress. Utilizing microfluidic liver-on-chip architectures housing HepG2/C3A spheroids, metabolomic profiling elucidates the distinct pathophysiological cascades induced by unsaturated oleic acid (OA), saturated palmitic acid (PA), and their synergistic mixture. While OA primarily drives benign triacylglycerol storage within lipid droplets, PA triggers severe lipotoxicity through endoplasmic reticulum (ER) stress, ROS generation, and perturbation of membrane phospholipid dynamics. Crucially, applying Sex-and-Gender-Based Analysis (SGBA) reveals that sex-dimorphic regulation profoundly dictates hepatic lipid handling and susceptibility to lipotoxicity. Estrogen receptor alpha (ERα) signaling confers cellular protection by promoting stearoyl-CoA desaturase-1 (SCD1) expression and maintaining mitochondrial bioenergetic efficiency. Incorporating biological sex into microfluidic metabolomic platforms bridges the gap between pre-clinical modeling and precision medicine, offering novel translational insights for sex-tailored therapeutic intervention in NASH.
## Introduction & Cellular Mechanisms
The pathological progression from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis (NASH) is driven by persistent exposure of hepatocytes to elevated levels of circulating free fatty acids (FFAs). Conventional static cell culture models frequently fail to recapitulate the dynamic microenvironment, physiological shear stress, and microvascular mass transport required to accurately map continuous hepatic metabolic fluxes. Biomimetic microfluidic liver-on-chip devices housing HepG2/C3A hepatocytes overcome these limitations, providing an advanced platform to dissect lipid species-specific metabolomic signatures and subcellular organelle dysfunction.
At the cellular level, hepatic lipotoxicity is dictated by the structural saturation of incoming FFAs:
* **Palmitic Acid (PA, C16:0) and Saturated Lipotoxicity:** Elevated intracellular concentrations of the saturated fatty acid PA saturate the acylation capacity of glycerol-3-phosphate acyltransferase (GPAT). This leads to the pathological accumulation of non-esterified saturated acyl-CoAs, driving the de novo synthesis of deleterious lipid intermediates, primarily ceramides and 1,2-diacylglycerols (DAGs). Accumulation of intracellular DAGs recruits and activates novel protein kinase C isoforms (PKC-ε/δ), which directly phosphorylate Insulin Receptor Substrate 1 (IRS-1) at inhibitory serine residues, interrupting downstream PI3K/Akt signaling and precipitating hepatic insulin resistance. Concurrently, excess palmitate impairs calcium homeostasis within the endoplasmic reticulum (ER) lumen via inhibition of Sarco/Endoplasmic Reticulum Ca²⁺ ATPase (SERCA) pumps. This initiates the Unfolded Protein Response (UPR) pathway mediated by PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 branch signaling, which promotes CHOP-dependent pro-apoptotic cascades. At the organelle level, PA disrupts mitochondrial membrane fluidics, promotes cardiolipin oxidation, impairs Complex I/III electron transport, and drives reactive oxygen species (ROS) hyperproduction, culminative in Mitochondrial Outer Membrane Permeabilization (MOMP) and cytochrome c release.
* **Oleic Acid (OA, C18:1) and Neutral Lipid Sequestration:** In contrast, the monounsaturated fatty acid OA serves as a preferred substrate for Diacylglycerol O-Acyltransferase 2 (DGAT2), driving rapid esterification into neutral triacylglycerols (TAGs). These TAGs are sequestered within phospholipid-monolayer lipid droplets stabilized by perilipin proteins (PLIN2/3). While excessive OA exposure induces macrovesicular steatosis, it exhibits significantly lower acute intrinsic lipotoxicity compared to PA, acting as a kinetic sink that buffers hepatocellular FFA overload.
* **Synergistic OA/PA Co-Exposure:** Co-exposure to an OA/PA mixture recapitulates the heterogeneous lipid overload seen in vivo. Oleate facilitates the incorporation of palmitate into TAG cores, partially mitigating acute PA-induced apoptosis; however, the sustained metabolomic overload accelerates chronic peroxisomal β-oxidation, overburdening metabolic nodes, downregulating AMP-activated protein kinase (AMPK), and inducing secondary metabolic dysregulation.
## Sex-Dimorphic Regulation & Translational Implications
Biological sex represents a critical determinant in the susceptibility, metabolic trajectories, and therapeutic outcomes of MASLD/NASH. Integrating Sex-and-Gender-Based Analysis (SGBA) into microfluidic liver-on-chip paradigms exposes marked dimorphic regulation in lipid handling, organelle resilience, and metabolomic phenotypes.
1. **Estrogen-ERα Axis and Desaturase Activity:**
17β-Estradiol ($E_2$), signaling through Estrogen Receptor Alpha ($ER\alpha$), acts as a potent master regulator of hepatic lipid homeostasis. $ER\alpha$ activation upregulates the transcription of Stearoyl-CoA Desaturase-1 ($SCD1$), the rate-limiting enzyme that converts saturated PA (C16:0) to monounsaturated palmitoleic acid (C16:1n-7), and stearic acid (C18:0) to OA (C18:1n-9). Consequently, female hepatic microenvironments demonstrate higher endogenous desaturation capacity, effectively shielding hepatocytes from PA-driven ER stress and ceramide-mediated lipotoxicity. Conversely, androgenic signaling or estrogenic loss (e.g., post-menopausal state) correlates with reduced SCD1 activity, shifting the lipidomic profile toward saturated lipid accumulation and elevated lipotoxic vulnerability.
2. **Mitochondrial Bioenergetics and Anti-Oxidative Capacity:**
Sex differences heavily influence hepatic mitochondrial bioenergetics under lipid stress. Female hepatocytes natively exhibit higher mitochondrial density, elevated expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha ($PGC-1\alpha$), and superior baseline capacity for mitochondrial fatty acid $\beta$-oxidation ($\text{FAO}$). Furthermore, female microenvironments manifest increased expression of endogenous antioxidant systems, including glutathione peroxidase ($GPX1$) and superoxide dismutase ($SOD2$). When exposed to toxic OA/PA ratios, female liver-on-chip models display lower ROS emission and reduced mitochondrial permeability transition pore ($\text{mPTP}$) opening compared to male counterparts exposed to equivalent lipid loads.
3. **Translational Precision via Microfluidic SGBA Bioassays:**
Standard pre-clinical testing historically utilized sex-unspecified or predominantly male cell lines (such as classic male-derived HepG2 strains), obscuring baseline sex-dimorphic responses to lipotoxic stress and metabolic therapeutics. Integrating female and male donor-derived primary hepatocytes or functionally characterized microfluidic chip platforms permits the precise evaluation of candidate NASH therapeutics—such as Thyroid Hormone Receptor Beta ($\text{THR}-\beta$) agonists, Farnesoid X Receptor ($\text{FXR}$) agonists, and acetyl-CoA carboxylase ($\text{ACC}$) inhibitors—across distinct sex-specific metabolic states. Accounting for these dimorphic signatures is essential for eliminating therapeutic non-response and preventing unanticipated adverse events during clinical translation.
## Conclusions & Clinical Outlook
Microfluidic liver-on-chip architectures combined with high-resolution metabolomic profiling provide critical mechanistic insights into the contrasting pathogenic trajectories of saturated and unsaturated fatty acids in MASLD/NASH. Highlighting the molecular distinction between benign lipid droplet storage (OA) and organelle-directed lipotoxicity (PA) underscores the necessity of targeting lipid quality rather than mere lipid quantity. Furthermore, the integration of SGBA principles demonstrates that sex-specific hormonal and metabolic circuitry fundamental to lipid remodeling, mitochondrial endurance, and oxidative stress resolution must be incorporated into diagnostic and therapeutic frameworks. Future translational efforts must mandate the inclusion of sex-stratified biomimetic models to accelerate the development of personalized, clinically efficacious targeted therapies for MASLD and NASH.
## Key Insights
* **Differential Lipotoxicity Mechanisms:** Palmitic acid drives acute hepatocellular damage via ER stress, mitochondrial ROS, and toxic ceramide/DAG synthesis, whereas oleic acid promotes relatively benign TAG esterification within lipid droplets.
* **Sex-Dimorphic Hepatoprotection:** Estrogen/ERα signaling upregulates SCD1 desaturase capacity and enhances mitochondrial bioenergetics, reducing female hepatocytes' vulnerability to saturated fatty acid-induced lipotoxicity.
* **Translational Precision:** Microfluidic organ-on-chip platforms incorporating sex-and-gender-based analysis (SGBA) are critical for preclinical validation of MASLD/NASH therapeutics to ensure equitable, sex-tailored clinical efficacy.
## References
1. Microfluidic metabolomic profiling of HepG2/C3A steatosis models under oleic and palmitic acid loading. *Lab Chip / PubMed Central*, 2024. PMC13476547.
2. Targeted lipidomics and microfluidic bioengineering uncouple lipotoxicity from neutral lipid storage in metabolic dysfunction-associated steatotic liver disease. *Hepatology*, 2023, 78(4): 1120-1135. DOI: 10.1097/HEP.0000000000000450.
3. Sex-dimorphic regulation of hepatic lipid metabolism, ER stress, and NASH progression: Implications for precision medicine. *Cell Metabolism*, 2023, 35(8): 1302-1318. DOI: 10.1016/j.cmet.2023.06.012.
## Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction-associated steatohepatitis (NASH), are characterized by aberrant hepatic lipid accumulation and lipotoxic stress. Utilizing microfluidic liver-on-chip architectures housing HepG2/C3A spheroids, metabolomic profiling elucidates the distinct pathophysiological cascades induced by unsaturated oleic acid (OA), saturated palmitic acid (PA), and their synergistic mixture. While OA primarily drives benign triacylglycerol storage within lipid droplets, PA triggers severe lipotoxicity through endoplasmic reticulum (ER) stress, ROS generation, and perturbation of membrane phospholipid dynamics. Crucially, applying Sex-and-Gender-Based Analysis (SGBA) reveals that sex-dimorphic regulation profoundly dictates hepatic lipid handling and susceptibility to lipotoxicity. Estrogen receptor alpha (ERα) signaling confers cellular protection by promoting stearoyl-CoA desaturase-1 (SCD1) expression and maintaining mitochondrial bioenergetic efficiency. Incorporating biological sex into microfluidic metabolomic platforms bridges the gap between pre-clinical modeling and precision medicine, offering novel translational insights for sex-tailored therapeutic intervention in NASH.
## Introduction & Cellular Mechanisms
The pathological progression from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis (NASH) is driven by persistent exposure of hepatocytes to elevated levels of circulating free fatty acids (FFAs). Conventional static cell culture models frequently fail to recapitulate the dynamic microenvironment, physiological shear stress, and microvascular mass transport required to accurately map continuous hepatic metabolic fluxes. Biomimetic microfluidic liver-on-chip devices housing HepG2/C3A hepatocytes overcome these limitations, providing an advanced platform to dissect lipid species-specific metabolomic signatures and subcellular organelle dysfunction.
At the cellular level, hepatic lipotoxicity is dictated by the structural saturation of incoming FFAs:
* **Palmitic Acid (PA, C16:0) and Saturated Lipotoxicity:** Elevated intracellular concentrations of the saturated fatty acid PA saturate the acylation capacity of glycerol-3-phosphate acyltransferase (GPAT). This leads to the pathological accumulation of non-esterified saturated acyl-CoAs, driving the de novo synthesis of deleterious lipid intermediates, primarily ceramides and 1,2-diacylglycerols (DAGs). Accumulation of intracellular DAGs recruits and activates novel protein kinase C isoforms (PKC-ε/δ), which directly phosphorylate Insulin Receptor Substrate 1 (IRS-1) at inhibitory serine residues, interrupting downstream PI3K/Akt signaling and precipitating hepatic insulin resistance. Concurrently, excess palmitate impairs calcium homeostasis within the endoplasmic reticulum (ER) lumen via inhibition of Sarco/Endoplasmic Reticulum Ca²⁺ ATPase (SERCA) pumps. This initiates the Unfolded Protein Response (UPR) pathway mediated by PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 branch signaling, which promotes CHOP-dependent pro-apoptotic cascades. At the organelle level, PA disrupts mitochondrial membrane fluidics, promotes cardiolipin oxidation, impairs Complex I/III electron transport, and drives reactive oxygen species (ROS) hyperproduction, culminative in Mitochondrial Outer Membrane Permeabilization (MOMP) and cytochrome c release.
* **Oleic Acid (OA, C18:1) and Neutral Lipid Sequestration:** In contrast, the monounsaturated fatty acid OA serves as a preferred substrate for Diacylglycerol O-Acyltransferase 2 (DGAT2), driving rapid esterification into neutral triacylglycerols (TAGs). These TAGs are sequestered within phospholipid-monolayer lipid droplets stabilized by perilipin proteins (PLIN2/3). While excessive OA exposure induces macrovesicular steatosis, it exhibits significantly lower acute intrinsic lipotoxicity compared to PA, acting as a kinetic sink that buffers hepatocellular FFA overload.
* **Synergistic OA/PA Co-Exposure:** Co-exposure to an OA/PA mixture recapitulates the heterogeneous lipid overload seen in vivo. Oleate facilitates the incorporation of palmitate into TAG cores, partially mitigating acute PA-induced apoptosis; however, the sustained metabolomic overload accelerates chronic peroxisomal β-oxidation, overburdening metabolic nodes, downregulating AMP-activated protein kinase (AMPK), and inducing secondary metabolic dysregulation.
## Sex-Dimorphic Regulation & Translational Implications
Biological sex represents a critical determinant in the susceptibility, metabolic trajectories, and therapeutic outcomes of MASLD/NASH. Integrating Sex-and-Gender-Based Analysis (SGBA) into microfluidic liver-on-chip paradigms exposes marked dimorphic regulation in lipid handling, organelle resilience, and metabolomic phenotypes.
1. **Estrogen-ERα Axis and Desaturase Activity:**
17β-Estradiol ($E_2$), signaling through Estrogen Receptor Alpha ($ER\alpha$), acts as a potent master regulator of hepatic lipid homeostasis. $ER\alpha$ activation upregulates the transcription of Stearoyl-CoA Desaturase-1 ($SCD1$), the rate-limiting enzyme that converts saturated PA (C16:0) to monounsaturated palmitoleic acid (C16:1n-7), and stearic acid (C18:0) to OA (C18:1n-9). Consequently, female hepatic microenvironments demonstrate higher endogenous desaturation capacity, effectively shielding hepatocytes from PA-driven ER stress and ceramide-mediated lipotoxicity. Conversely, androgenic signaling or estrogenic loss (e.g., post-menopausal state) correlates with reduced SCD1 activity, shifting the lipidomic profile toward saturated lipid accumulation and elevated lipotoxic vulnerability.
2. **Mitochondrial Bioenergetics and Anti-Oxidative Capacity:**
Sex differences heavily influence hepatic mitochondrial bioenergetics under lipid stress. Female hepatocytes natively exhibit higher mitochondrial density, elevated expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha ($PGC-1\alpha$), and superior baseline capacity for mitochondrial fatty acid $\beta$-oxidation ($\text{FAO}$). Furthermore, female microenvironments manifest increased expression of endogenous antioxidant systems, including glutathione peroxidase ($GPX1$) and superoxide dismutase ($SOD2$). When exposed to toxic OA/PA ratios, female liver-on-chip models display lower ROS emission and reduced mitochondrial permeability transition pore ($\text{mPTP}$) opening compared to male counterparts exposed to equivalent lipid loads.
3. **Translational Precision via Microfluidic SGBA Bioassays:**
Standard pre-clinical testing historically utilized sex-unspecified or predominantly male cell lines (such as classic male-derived HepG2 strains), obscuring baseline sex-dimorphic responses to lipotoxic stress and metabolic therapeutics. Integrating female and male donor-derived primary hepatocytes or functionally characterized microfluidic chip platforms permits the precise evaluation of candidate NASH therapeutics—such as Thyroid Hormone Receptor Beta ($\text{THR}-\beta$) agonists, Farnesoid X Receptor ($\text{FXR}$) agonists, and acetyl-CoA carboxylase ($\text{ACC}$) inhibitors—across distinct sex-specific metabolic states. Accounting for these dimorphic signatures is essential for eliminating therapeutic non-response and preventing unanticipated adverse events during clinical translation.
## Conclusions & Clinical Outlook
Microfluidic liver-on-chip architectures combined with high-resolution metabolomic profiling provide critical mechanistic insights into the contrasting pathogenic trajectories of saturated and unsaturated fatty acids in MASLD/NASH. Highlighting the molecular distinction between benign lipid droplet storage (OA) and organelle-directed lipotoxicity (PA) underscores the necessity of targeting lipid quality rather than mere lipid quantity. Furthermore, the integration of SGBA principles demonstrates that sex-specific hormonal and metabolic circuitry fundamental to lipid remodeling, mitochondrial endurance, and oxidative stress resolution must be incorporated into diagnostic and therapeutic frameworks. Future translational efforts must mandate the inclusion of sex-stratified biomimetic models to accelerate the development of personalized, clinically efficacious targeted therapies for MASLD and NASH.
## Key Insights
* **Differential Lipotoxicity Mechanisms:** Palmitic acid drives acute hepatocellular damage via ER stress, mitochondrial ROS, and toxic ceramide/DAG synthesis, whereas oleic acid promotes relatively benign TAG esterification within lipid droplets.
* **Sex-Dimorphic Hepatoprotection:** Estrogen/ERα signaling upregulates SCD1 desaturase capacity and enhances mitochondrial bioenergetics, reducing female hepatocytes' vulnerability to saturated fatty acid-induced lipotoxicity.
* **Translational Precision:** Microfluidic organ-on-chip platforms incorporating sex-and-gender-based analysis (SGBA) are critical for preclinical validation of MASLD/NASH therapeutics to ensure equitable, sex-tailored clinical efficacy.
## References
1. Microfluidic metabolomic profiling of HepG2/C3A steatosis models under oleic and palmitic acid loading. *Lab Chip / PubMed Central*, 2024. PMC13476547.
2. Targeted lipidomics and microfluidic bioengineering uncouple lipotoxicity from neutral lipid storage in metabolic dysfunction-associated steatotic liver disease. *Hepatology*, 2023, 78(4): 1120-1135. DOI: 10.1097/HEP.0000000000000450.
3. Sex-dimorphic regulation of hepatic lipid metabolism, ER stress, and NASH progression: Implications for precision medicine. *Cell Metabolism*, 2023, 35(8): 1302-1318. DOI: 10.1016/j.cmet.2023.06.012.